Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 4 4Phase 3 4Phase NA 2Phase 2/3 2Phase 1/2 2Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Adrenal Cortex Hormones × Clear all
NCT05789589 2026-03-04

ADORATION

Baptist Health South Florida

Phase 1/2 Recruiting
46 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02802163 2017-04-25

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡